276 related articles for article (PubMed ID: 8083980)
1. Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes.
Taylor KA; Wetzel S; Lyles DS; Pollok BA
J Virol; 1994 Oct; 68(10):6421-31. PubMed ID: 8083980
[TBL] [Abstract][Full Text] [Related]
2. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
Nilsson T; Sjöblom A; Masucci MG; Rymo L
Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
[TBL] [Abstract][Full Text] [Related]
3. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
4. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
[TBL] [Abstract][Full Text] [Related]
6. Integration of a short Epstein-Barr virus DNA fragment in a B95-8 virus converted Burkitt lymphoma line expressing Epstein-Barr nuclear antigens EBNA2 and EBNA5.
Trivedi P; Cuomo L; de Campos-Lima PO; Imreh MP; Kvarnung K; Klein G; Masucci MG
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1393-8. PubMed ID: 8393080
[TBL] [Abstract][Full Text] [Related]
7. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
Brooks L; Yao QY; Rickinson AB; Young LS
J Virol; 1992 May; 66(5):2689-97. PubMed ID: 1313894
[TBL] [Abstract][Full Text] [Related]
9. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes.
Schaefer BC; Woisetschlaeger M; Strominger JL; Speck SH
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6550-4. PubMed ID: 1713681
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
Deacon EM; Pallesen G; Niedobitek G; Crocker J; Brooks L; Rickinson AB; Young LS
J Exp Med; 1993 Feb; 177(2):339-49. PubMed ID: 8381153
[TBL] [Abstract][Full Text] [Related]
11. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
[TBL] [Abstract][Full Text] [Related]
12. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines.
Jansson A; Masucci M; Rymo L
J Virol; 1992 Jan; 66(1):62-9. PubMed ID: 1370095
[TBL] [Abstract][Full Text] [Related]
13. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.
Nonkwelo C; Skinner J; Bell A; Rickinson A; Sample J
J Virol; 1996 Jan; 70(1):623-7. PubMed ID: 8523583
[TBL] [Abstract][Full Text] [Related]
14. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Puglielli MT; Woisetschlaeger M; Speck SH
J Virol; 1996 Sep; 70(9):5758-68. PubMed ID: 8709191
[TBL] [Abstract][Full Text] [Related]
15. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.
Schaefer BC; Strominger JL; Speck SH
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10565-9. PubMed ID: 7479841
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
Tierney RJ; Steven N; Young LS; Rickinson AB
J Virol; 1994 Nov; 68(11):7374-85. PubMed ID: 7933121
[TBL] [Abstract][Full Text] [Related]
18. Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells.
Smith PR; Griffin BE
J Virol; 1992 Feb; 66(2):706-14. PubMed ID: 1370554
[TBL] [Abstract][Full Text] [Related]
19. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
[TBL] [Abstract][Full Text] [Related]
20. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.
Kerr BM; Lear AL; Rowe M; Croom-Carter D; Young LS; Rookes SM; Gallimore PH; Rickinson AB
Virology; 1992 Mar; 187(1):189-201. PubMed ID: 1310556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]